OKYO Pharma annual stock-based compensation
2020
2021
2022
2023
2024
2025
2026
OKYO Pharma Stock-Based Compensation Growth & History (OKYO)
OKYO Pharma's stock-based compensation was $1.6M for fiscal 2026.
View full OKYO Pharma company overviewOKYO Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.6M | $870,271 | +118.41% |
| 2025 | 2025-03-31 | $734,989 | −$386,284 | −34.45% |
| 2024 | 2024-03-31 | $1.1M | −$164,855 | −12.82% |
| 2023 | 2023-03-31 | $1.3M | −$451,748 | −25.99% |
| 2022 | 2022-03-31 | $1.7M | $1.2M | +215.90% |
| 2021 | 2021-03-31 | $550,138 | $513,798 | +1413.86% |
| 2020 | 2020-03-31 | $36,340 | — | — |
OKYO Pharma stock-based compensation trends
Over the last five fiscal years, OKYO Pharma's stock-based compensation increased from $550,138 to $1.6M, a change of $1.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OKYO Pharma source filings ↗